Namilumab clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses namilumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 2 |
| 2018 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Takeda (3) · Kinevant Sciences GmbH (2) · Izana Bioscience Ltd. (1)
Studies
Open first, then newest update. How each study uses namilumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary SarcoidosisTerminatedPhase 2Kinevant Sciences GmbHNCT05314517Written as Namilumab
- A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac SarcoidosisTerminatedPhase 2Kinevant Sciences GmbHNCT05351554Written as Namilumab
- Efficacy and Safety of Namilumab for Moderate-to-severe Axial SpondyloarthritisCompletedPhase 2Izana Bioscience Ltd.NCT03622658Written as Namilumab
- Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)CompletedPhase 2TakedaNCT02379091Written as Namilumab
- Efficacy and Safety of Namilumab (MT203) for Plaque PsoriasisCompletedPhase 2TakedaNCT02129777Written as Namilumab
- A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid ArthritisCompletedPhase 1TakedaNCT01317797Written as namilumab (MT203)
As the comparator · 1 — what is tested is compared with namilumab
Codes
What other systems call namilumab · ClinicalTrials.gg INT000834
- MeSH (NLM) C000624713namilumabOne source NLM
- UNII (FDA) MED485W763NAMILUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6961860namilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97943NamilumabOne source FDA
- DrugBank DB13037One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624713 | namilumab | One source NLM |
| UNII (FDA) | MED485W763 | NAMILUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6961860 | namilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97943 | Namilumab | One source FDA |
| DrugBank | DB13037 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.